Literature DB >> 23475559

STP position paper: Recommended practices for sampling and processing the nervous system (brain, spinal cord, nerve, and eye) during nonclinical general toxicity studies.

Brad Bolon1, Robert H Garman, Ingrid D Pardo, Karl Jensen, Robert C Sills, Aude Roulois, Ann Radovsky, Alys Bradley, Lydia Andrews-Jones, Mark Butt, Laura Gumprecht.   

Abstract

The Society of Toxicologic Pathology charged a Nervous System Sampling Working Group with devising recommended practices to routinely screen the central nervous system (CNS) and peripheral nervous system (PNS) in Good Laboratory Practice-type nonclinical general toxicity studies. Brains should be weighed and trimmed similarly for all animals in a study. Certain structures should be sampled regularly: caudate/putamen, cerebellum, cerebral cortex, choroid plexus, eye (with optic nerve), hippocampus, hypothalamus, medulla oblongata, midbrain, nerve, olfactory bulb (rodents only), pons, spinal cord, and thalamus. Brain regions may be sampled bilaterally in rodents using 6 to 7 coronal sections, and unilaterally in nonrodents with 6 to 7 coronal hemisections. Spinal cord and nerves should be examined in transverse and longitudinal (or oblique) orientations. Most Working Group members considered immersion fixation in formalin (for CNS or PNS) or a solution containing acetic acid (for eye), paraffin embedding, and initial evaluation limited to hematoxylin and eosin (H&E)-stained sections to be acceptable for routine microscopic evaluation during general toxicity studies; other neurohistological methods may be undertaken if needed to better characterize H&E findings. Initial microscopic analyses should be qualitative and done with foreknowledge of treatments and doses (i.e., "unblinded"). The pathology report should clearly communicate structures that were assessed and methodological details. Since neuropathologic assessment is only one aspect of general toxicity studies, institutions should retain flexibility in customizing their sampling, processing, analytical, and reporting procedures as long as major neural targets are evaluated systematically.

Entities:  

Keywords:  CNS; GLP; PNS; brain; brain weight; eye; general toxicity study; nervous system; neuropathology; neurotoxicity; nonclinical toxicity study; recommended practices; spinal cord.

Mesh:

Year:  2013        PMID: 23475559     DOI: 10.1177/0192623312474865

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  34 in total

1.  In Vivo Imaging With Confirmation by Histopathology for Increased Rigor and Reproducibility in Translational Research: A Review of Examples, Options, and Resources.

Authors:  Kathleen Gabrielson; Robert Maronpot; Sébastien Monette; Coraline Mlynarczyk; Yuval Ramot; Abraham Nyska; Polina Sysa-Shah
Journal:  ILAR J       Date:  2018-12-01

2.  White Matter is the Predilection Site of Late-Delayed Radiation-Induced Brain Injury in Non-Human Primates.

Authors:  Rachel N Andrews; Gregory O Dugan; Ann M Peiffer; Gregory A Hawkins; David B Hanbury; J Daniel Bourland; Robert E Hampson; Samuel A Deadwyler; J Mark Clinea
Journal:  Radiat Res       Date:  2019-01-29       Impact factor: 2.841

3.  Quantitative mapping of trimethyltin injury in the rat brain using magnetic resonance histology.

Authors:  G Allan Johnson; Evan Calabrese; Peter B Little; Laurence Hedlund; Yi Qi; Alexandra Badea
Journal:  Neurotoxicology       Date:  2014-03-11       Impact factor: 4.294

Review 4.  Animal models of peripheral neuropathy due to environmental toxicants.

Authors:  Deepa B Rao; Bernard S Jortner; Robert C Sills
Journal:  ILAR J       Date:  2014

5.  Qualitative and Quantitative Neuropathology Approaches Using Magnetic Resonance Microscopy (Diffusion Tensor Imaging) and Stereology in a Hexachlorophene Model of Myelinopathy in Sprague-Dawley Rats.

Authors:  Robert C Sills; G Allan Johnson; Robert J Anderson; Crystal L Johnson; Michael Staup; Danielle L Brown; Sheba R Churchill; David M Kurtz; Jesse D Cushman; Suramya Waidyanatha; Veronica Godfrey Robinson; Mark F Cesta; Danica M K Andrews; Mamta Behl; Keith R Shockley; Peter B Little
Journal:  Toxicol Pathol       Date:  2020-12-02       Impact factor: 1.902

6.  Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.

Authors:  Lauren E Himmel; Maryam B Lustberg; A Courtney DeVries; Ming Poi; Ching-Shih Chen; Samuel K Kulp
Journal:  Exp Toxicol Pathol       Date:  2016-08-21

7.  1,3-dinitrobenzene induces age- and region-specific oxidation to mitochondria-related proteins in brain.

Authors:  Laura L Kubik; Rory W Landis; Henriette Remmer; Ingrid L Bergin; Martin A Philbert
Journal:  Toxicol Sci       Date:  2015-02-24       Impact factor: 4.849

8.  Juvenile Toxicology: Relevance and Challenges for Toxicologists and Pathologists.

Authors:  Amera K Remick; Natasha R Catlin; Erin M Quist; Thomas J Steinbach; Darlene Dixon
Journal:  Toxicol Pathol       Date:  2015-07-27       Impact factor: 1.902

9.  Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury.

Authors:  Rachel N Andrews; David L Caudell; Linda J Metheny-Barlow; Ann M Peiffer; Janet A Tooze; J Daniel Bourland; Robert E Hampson; Samuel A Deadwyler; J Mark Cline
Journal:  Radiat Res       Date:  2018-07-17       Impact factor: 2.841

10.  Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Authors:  Syed Z Imam; Zhen He; Elvis Cuevas; Hector Rosas-Hernandez; Susan M Lantz; Sumit Sarkar; James Raymick; Bonnie Robinson; Joseph P Hanig; David Herr; Denise MacMillan; Aaron Smith; Serguei Liachenko; Sherry Ferguson; James O'Callaghan; Diane Miller; Christopher Somps; Ingrid D Pardo; William Slikker; Jennifer B Pierson; Ruth Roberts; Binsheng Gong; Weida Tong; Michael Aschner; Mary J Kallman; David Calligaro; Merle G Paule
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.